

2011 Physician Quality Reporting System (Physician Quality Reporting)
Previously known as Physician Quality Reporting Initiative (PQRI)
Group Practice Reporting Option I (GPRO I) Narrative Specification Release Notes

CMS is pleased to announce the release of the 2011 Physician Quality Reporting GPRO I Narrative Specification Release Notes. The list below details changes to existing measures made since the release of the 2010 PQRI Narrative Measure Specifications, Version 1.1. These Release Notes correspond to version 2.0 of the posted 2011 Physician Quality Reporting GPRO I Narrative Specifications.

GPRO DM-1: Diabetes Mellitus: Hemoglobin A1c Testing
NO CHANGES

GPRO DM-2: Diabetes Mellitus: Hemoglobin A1c Poor Control in Diabetes Mellitus
NO CHANGES

GPRO DM-3: Diabetes Mellitus: High Blood Pressure Control in Diabetes Mellitus
• Updated Description and Numerator Statement – to include less than 140/90 mmHg

GPRO DM-5: Diabetes Mellitus: Low Density Lipoprotein (LDL-C) Control in Diabetes Mellitus
NO CHANGES

GPRO DM-6: Diabetes Mellitus: Urine Screening for Microalbumin or Medical Attention for Nephropathy in Diabetic Patients
NO CHANGES

GPRO DM-7: Diabetes Mellitus: Dilated Eye Exam in Diabetic Patient
NO CHANGES

GPRO DM-8: Diabetes Mellitus: Foot Exam
NO CHANGES

GPRO DM-9: Diabetes Mellitus: Lipid Profile
NO CHANGES

GPRO HF-1: Heart Failure: Left Ventricular Function (LVF) Assessment
NO CHANGES

GPRO HF-2: Heart Failure: Left Ventricular Function (LVF) Testing
NO CHANGES

GPRO HF-3: Heart Failure: Weight Measurement
NO CHANGES

GPRO HF-5: Heart Failure: Patient Education
NO CHANGES

GPRO HF-6: Heart Failure: Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
NO CHANGES

GPRO HF-7: Heart Failure: Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
NO CHANGES

GPRO HF-8: Heart Failure: Warfarin Therapy for Patients with Atrial Fibrillation
NO CHANGES

GPRO CAD-1: Coronary Artery Disease (CAD): Oral Antiplatelet Therapy Prescribed for Patients with CAD
NO CHANGES

GPRO CAD-2: Coronary Artery Disease (CAD): Drug Therapy for Lowering LDL-Cholesterol
NO CHANGES

GPRO CAD-3: Coronary Artery Disease (CAD): Beta-Blocker Therapy for CAD Patients with Prior Myocardial Infarction (MI)
NO CHANGES

GPRO CAD-7: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy for Patients with CAD and Diabetes and/or Left Ventricular Systolic Dysfunction (LVSD)
NO CHANGES

GPRO HTN-1: Hypertension (HTN): Blood Pressure Measurement
NO CHANGES

GPRO HTN-2: Hypertension (HTN): Blood Pressure Control
NO CHANGES

GPRO HTN-3: Hypertension (HTN): Plan of Care
NO CHANGES

GPRO Prev-5: Preventive Care and Screening: Screening Mammography
NO CHANGES

GPRO Prev-6: Preventive Care and Screening: Colorectal Cancer Screening
NO CHANGES

GPRO Prev-7: Preventive Care and Screening: Influenza Immunization for Patients ≥ 50 Years Old
NO CHANGES

GPRO Prev-8: Preventive Care and Screening: Pneumonia Vaccination for Patients 65 Years and Older
NO CHANGES

Global Edits

- Denominator section including statement moved to follow description
- Reference to measure owner at bottom of each specification removed as it is noted by a symbol at the beginning of each specification